BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 23, 2010
View Archived Issues
Preclinical data presented on Radius Health's SARM RAD-140
Read More
New class of toluidine sulfonamides set to enter clinical testing for the treatment of MM
Read More
New ligands of dopamine and/or serotonin 5-HT1A receptors reported
Read More
French scientists claim new cannabinoid CB2 receptor agonists
Read More
New inhibitors of HCV RNA-directed RNA polymerase claimed
Read More
Actelion discloses new agonists of formylpeptide FPR2/ALX receptors
Read More
Vertex modifies phase II trial of telaprevir plus VX-222 against hepatitis C
Read More
FBS-0701 is safe in phase Ib study in subjects with iron overload, phase II trial under way
Read More
Pan-5-HT1 receptor antagonist GSK-163090 progresses to clinical development
Read More
Potent analgesic activity seen with KD-7332 in vitro and in vivo
Read More
Novo Nordisk and Emisphere to develop oral insulin for diabetes
Read More
Applications for abiraterone acetate submitted to FDA and EMA
Read More
Oncothyreon begins phase I/II trial of PX-866/cetuximab combination
Read More
CHMP recommends approval of Teysuno for treatment of advanced gastric cancer
Read More
Ambit Biosciences begins phase I trials for AC-430 and AC-480
Read More
Chugai and Dainippon Sumitomo to conduct phase I/II trial of cancer vaccine WT-4869
Read More
CHMP recommends a variation to marketing terms for Simponi
Read More
CHMP recommends marketing authorization for Janssen-Cilag's Xeplion
Read More
Merck & Co. identifies new inhibitors of PDE10A
Read More
AstraZeneca discontinues motavizumab development for RSV
Read More
DSMB recommends continuation of phase II AX-200 efficacy trial
Read More
MAP Pharmaceuticals completes final trial for Levadex NDA submission
Read More
Isis begins phase I ISIS-APOCIIIRx trial to treat hypertriglyceridemia
Read More
Amarillo Biosciences to study oral interferon and Tamiflu for influenza
Read More
Amylin submits initial sections of rolling BLA for metreleptin
Read More